

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

E APPLICANT

: Jackowski et al.

INVENTION:

: APOLIPOPROTEIN BIOPOLYMER MARKERS

PREDICTIVE OF ALZHEIMERS DISEASE RECEIVED

MAY 0 2 2003

TECH CENTER 1600/2900

SERIAL NUMBER

: 10/020,008

FILING DATE

: December 13, 2001

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1645

ATTORNEY DOCKET NO.

: 2132.089

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner fo Patents, Washington, D.C. 20231 on

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please find enclosed for filing:

Supplemental Information Disclosure Statement

Certification Pursuant to 37 C.F.R. §1.97(e)

Copy of International Search Report

PTO-1449

References

Respectfully Submitted,

Date: 4/28/2003

Ferris H. Lander

Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANT

: Jackowski et al.

INVENTION:

APOLIPOPROTEIN BIOPOLINIES.....
PREDICTIVE OF ALZHEIMERS DISEASE RECEIVED : APOLIPOPROTEIN BIOPOLYMER MARKERS

SERIAL NUMBER

: 10/020,008

FILING DATE

: December 13, 2001

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1645

ATTORNEY DOCKET NO.

: 2132.089

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date: _ 4/20/2003

Respectfully Submitted,

Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575





: Jackowski et al.

INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKERS

PREDICTIVE OF ALZHEIMERS DISEASE

SERIAL NUMBER : 10/020,008

FILING DATE : December 13, 2001

EXAMINER: : (not assigned yet)

GROUP ART UNIT : 1645

ATTORNEY DOCKET NO. : 2132.089

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 1995

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date: 4/28/2003

Respectfully Submitted,

Ferris H. Lander Reg. No. 43,377 McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

RMATION DISCLOS		Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				APPLICATION NO. 10/020,008		
BY APPLICANT				JACKOWSKI et al.				
(Use several sheets if necessary)			12/13/01			GROUP 1645		
	U.S. PA	TENT DOCUMENTS			<u> </u>			
DOCUMENT NUMBER	DATE	NAME		CLASS	RE	S PARTY OF THE PER	DATE	
							VE	
					177	AY 02	2000	
					TECH C	ENTER 1	60011	
							000/2	
			·					
DOCUMENT NUMBER	DATE COUNTRY			CLASS	SUBCLASS	TRANSI	ATION	
	00.00					YES	NO	
							+	
						 	+,	
WO 01/05422	01/01	PCI					<u>X</u>	
OTUES DOCUME	NTO ((/	Aught Title Date	<u> </u>		54- I			
							· /	
						nset Aizhe	uner s	
are increased a	t follow up and	d show a correlation v						
	DOCUMENT NUMBER WO 93/31227 WO 00/49410 WO 01/05422 OTHER DOCUME Merched, et al., disease", J. Ne Lindh, et al., "Care increased a	DOCUMENT NUMBER DATE DOCUMENT NUMBER DATE DOCUMENT NUMBER DATE WO 93/31227 O6/99 WO 00/49410 O8/00 WO 01/05422 O1/01 OTHER DOCUMENTS (Including Merched, et al., "Cerebrospin disease", J. Neurological Scientific are increased at follow up and	DOCUMENT NUMBER DATE COUNTRY WO 93/31227 O6/99 PCT WO 00/49410 O8/00 PCT WO 01/05422 O1/01 PCT OTHER DOCUMENTS (Including Author, Title, Date, Merched, et al., "Cerebrospinal fluid apolipoprotein disease", J. Neurological Sciences (1997) Vol. 145 Lindh, et al., "Cerebrospinal fluid apolipoprotein E (DOCUMENT NUMBER DATE COUNTRY WO 93/31227 O6/99 PCT WO 00/49410 O8/00 PCT WO 01/05422 O1/01 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent disease", J. Neurological Sciences (1997) Vol. 145, No. 1, Lindh, et al., "Cerebrospinal fluid apolipoprotein E level is disease", J. Neurological Sciences (1997) Vol. 145, No. 1, Lindh, et al., "Cerebrospinal fluid apolipoprotein E (apoE) levare increased at follow up and show a correlation with level Letters (1997) Vol. 229, No. 2, pp. 85-88.	DOCUMENT NUMBER DATE DOCUMENT NUMBER DATE COUNTRY CLASS WO 93/31227 O6/99 PCT WO 00/49410 O8/00 PCT WO 01/05422 O1/01 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Identification of the process	DOCUMENT NUMBER DATE NAME CLASS M TECH CI DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS WO 93/31227 O6/99 PCT WO 00/49410 08/00 PCT WO 01/05422 01/01 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Merched, et al., "Cerebrospinal fluid apolipoprotein E level is increased in late-odisease", J. Neurological Sciences (1997) Vol. 145, No. 1, pp. 33-39. Lindh, et al., "Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's dare increased at follow up and show a correlation with levels of tau protein", N Letters (1997) Vol. 229, No. 2, pp. 85-88.	DOCUMENT NUMBER DATE NAME CLASS MAY 0 2 TECH CEN TERT 1 DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRAINSI YES WO 93/31227 O6/99 PCT X WO 00/49410 08/00 PCT X WO 01/05422 O1/01 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Merched, et al., "Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzhe disease", J. Neurological Sciences (1997) Vol. 145, No. 1, pp. 33-39. Lindh, et al., "Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease pati are increased at follow up and show a correlation with levels of tau protein", Neuroscienc Letters (1997) Vol. 229, No. 2, pp. 85-88.	

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.